It’s no surprise really, the change in the law came about through pressure from families with children suffering from untreatable conditions rather than a realisation on behalf of conservatives that it is widely understood that cannabis is medically beneficial to the majority of the population, they know this already but the priority with these people is always to control the flow of wealth in their direction.
This to me is why Kanabo is such an attractive investment, if and when they receive CE approval we will be invested in the only company with access to the Uk health market with a device able to deliver a measured dose time after time of a quality assured medical grade cannabinoid infusion. It’s about as far away as you can get from the recreational market so should allow for a more open medical market (hopefully NHS) while still allowing them to continue with the prohibition of recreational use.
A good RNS outlining the solid structure of Kanabo. Also helpful to see a timeline for crop capacity. Will be interesting to see contracts coming in over the next two years.
It’s a good long term building block but understandable that it hasn’t had a positive effect on the SP. With a potential to produce 3000kg in two years, that’s assuming the upcoming Spanish elections don’t derail the cannabis train.
As mentioned on another site, it’s interesting to compare this with HELD which KNB also have an interest in. Their annual harvest capacity is 55,000kg from a facility in Greece where there’s no likelihood of the government derailing the project and the cost of production is far lower. And they are already producing with a harvest due shortly.
Good shout on HELD
The Cannabis Industry Council raisong the flag to improve legislation on prescribing cannabis
Can you imagine where the KNB share price would be if they were to receive CE approval for the vape pod and then for the government to announce GP’s will be allowed to prescribe cannabis. What could be more attractive to an inexperienced practitioner than a metered dose device with numerous variations on cannabinoid and terpene profiles each one designed to target specific conditions. Or you might opt to prescribe some flower or a bottle of oil.
I am starting to enjoy the current share price. All the news about legislation is pointing towards increased uptake and outlining the increased need.
Kanabo are very good at keeping their powder dry and have a near absent marketing drive. Ive made my peace with this also. I’m hoping that Mattioli was brought in to lay the tracks for the CE mark, so thwt when it drops there is actually a market response. In any case, I see no reason to sell.
Call me cynical but I expect the Tories to use the relaxation of GP’s proscribing of cannabis to coincide with the upcoming GE. They don’t have much going for them so a change or promise of change should they be re-elected. We know it’s coming and we know they like to use this kind of leverage, we had a Tory MP on the board of directors guiding us through the regulatory hurdles, his work done he steps down and now we have Mr Mattioli the astute business man on board to ensure things all run to plan.
This is interesting, Israeli cannabis company Syqe medical being bought out by tobacco giant Philip Morris in a deal worth up to $650million. And what do they have but a metered dose vaporiser, they claim it’s unique but follow the links and I don’t see any advantage over Kanabo vape pod. It’s different more expensive more complex more expensive less discrete from what I have read. What I find very comforting is this company spent a couple of years contemplating the best route into the medical cannabis market and chose vaping, I guess as they already had an interest in Syqe and Kanabo not being for sale they have gone with what they know, but I can’t see the advantage of this equipment and it has yet to go through trials before it can be sold in the USA. So for me this gives serious validation to the route to market Kanabo have chosen. It’s all on the CE mark which hopefully is not too far off from validation. https://mjbizdaily.com/philip-morris-buying-israeli-cannabis-firm-for-up-to-650m-report-says/
Thank you for sharing, this is encouraging news. I see that the vaporiser has approval in Canada and Israel (for veterans). Going back to your cynical point, it would seem politically short sighted not to grant the CE mark in this nascent industry (iff the government are serious about looking for a competitive edge).
Im not indoctrinated into the world of vaping. I wonder how compatibility works? Would Kanabo’s machine be able to take cartridges from other medicines? Id imagine if Philip Morris are your competition you are gonna need some flex.
Hi Chris, From what I have gathered from looking into the grading of the CE mark it’s all about the data and after so long I would be surprised and dismayed if it were to fail at this late stage. This government clearly want to take a medicinal route only at the moment and as someone with a lot of knowledge about vaping and it’s medicinal benefits I see Kanabo as the conservatives answer, a medical grade device delivering a repeat measured dose which is tamper secure and no the vape pod is not able to take standard size cartridges but this is a positive under the circumstances, I don’t see the vape pod as an attractive option for the recreational user.From what I can make out of the Syqe inhaler it is also unique in its form and function so in that regard they are similar. I would love to be able to test them but that’s not possible so let’s assume they are on a par when it comes to their suitability for medical use.
I don’t See them as being in competition because they are both looking to different markets, both have medical grade status in Israel which is broadly the same as CE mark and are trying to gain access to a wider market. Kanabo are late stage in this process and their target is Europe whereas Syqe are looking to gain a foothold in the USA. If Syqe should choose to target the European market they would need to apply for the CE mark which takes about two years so they are no threat to Kanabo.
Lookin at the deal they have agreed if it were Kanabo then I would expect the share price would probably be £1.00 rather than 0.02 so I am very comfortable with going long here. AIMO DYOR 
Thank you Geoff, I appreciate the additional context. And I think like yoursel, Im sanguine about the current share price and enthusiastic about what will happen iff the CE mark gets a thumbs up.
According to information on the Syqe website their inhaler, I use that description because it actually uses the whole flower rather than extract so significantly different from Kanabo. They appear to have CE mark for Europe and claim to be the only ones with a medical device.
It’s interesting but I don’t see this as a threat to Kanabo, it’s another way of obtaining medical benefit but not in my view superior.
https://syqe.com/routes-of-administration-and-how-to-use/
Astoundingly good news
That is good news, time to start searching for a CBD flower supplier in Europe.
After that SYQE deal I searched for other companies from Israel involved in the cannabis industry. You might find this interesting. They are definitely ahead of the game when it comes to cannabis research and development. Also you can compare what each company is focused on and all looks good for Kanabo.
Share issuance hitting the market on 26th. The RNS mentions Mattioli and other directors will be getting in for around 2.88p. But I suspect this will be seen by the market as a dilution and the share price will dip, or is this already priced in?
If the SP drops I will take it as a buying opportunity 
Albania on board with legislation
We need a government that’s fit for the job. UK is world's largest producer of legal cannabis | UK News | Sky News